Clinical Outcomes After Definitive Treatment of Soft Tissue Sarcoma of the Hand: A Retrospective Cohort Study of 109 Patients

被引:0
作者
Chapman, Talia R. [1 ]
Lavery, Jessica A. [2 ]
Nolan, John E. [1 ,3 ]
Athanasian, Edward A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
[3] Northwell Hlth, Dept Surg, New Hyde Pk, NY USA
来源
JOURNAL OF HAND SURGERY-AMERICAN VOLUME | 2024年 / 49卷 / 09期
关键词
Hand; recurrence; sarcoma; soft tissue sarcoma; surgical resection; COMPLICATIONS;
D O I
10.1016/j.jhsa.2024.05.003
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Purpose The purpose of this study was to provide updated data on oncologic outcomes following definitive surgical treatment of soft tissue sarcoma of the hand in a cohort of 109 patients, as well as to characterize risk factors for poor oncologic and functional outcomes. Methods We analyzed data from 109 consecutive patients who had definitive surgical treatment for soft tissue sarcoma of the hand performed between 1996 and 2019 by a single surgeon at a sarcoma center. Primary outcomes included functional outcome (assessed by Musculoskeletal Tumor Society scores), disease-free survival (DFS), and overall survival (OS). We compiled descriptive data and used a multivariable linear model to identify factors associated with functional outcomes. Kaplan-Meier methods were used to estimate 5and 10- year DFS and OS. Results Patients had a median age of 36 years at presentation. Median follow-up was 6.1 years among patients alive at the end of follow-up. The median Musculoskeletal Tumor Society score was 29; functional outcome was worse among patients with high-grade tumors or complications. Among the 107 patients who became disease-free, there were four local recurrences (one with metastasis), six distant recurrences, and one death without recurrence. All local recurrences were deep tumors (two myxofibrosarcoma and two myxoinflammatory fibrosarcoma). Estimated 5and 10-year DFS rates were 89% (95% confidence interval [CI]: 83% to 96%) and 88% (95% CI: 80% to 95%). There were seven deaths, and the estimated 5and 10-year OS rates were 95% (95% CI: 90% to 100%) and 92% (95% CI: 84% to 100%). Larger tumor size and higher stage at diagnosis were associated with shorter DFS and OS in univariable analyses; low event rates precluded multivariable analysis of survival. Conclusions Aggressive disease-specific surgical and multidisciplinary treatment can yield long DFS and OS, and good functional outcomes. However, complications and high-grade tumors are associated with worse functional scores.
引用
收藏
页码:867 / 874
页数:8
相关论文
共 50 条
  • [31] A Retrospective Analysis of Systemic Oncologic Treatment in Older Patients With Advanced Soft-tissue Sarcoma
    Lemma, Jasmiini
    Liljestrom, Jasmin
    Sampo, Mika
    Nevala, Riikka
    Blomqvist, Carl
    Elmegiri, Mohamed
    Jaamaa, Sari
    ANTICANCER RESEARCH, 2024, 44 (07) : 3067 - 3075
  • [32] Is there a place for definitive radiotherapy in the treatment of unresectable soft-tissue sarcoma? A systematic review
    Allignet, Benoit
    Sunyach, Marie-Pierre
    Geets, Xavier
    Waissi, Waisse
    ACTA ONCOLOGICA, 2022, 61 (06) : 720 - 729
  • [33] Treatment Strategy for Elderly Patients with Soft Tissue Sarcoma
    Tomoki Nakamura
    Akihiro Sudo
    Current Oncology Reports, 2022, 24 : 563 - 571
  • [34] Treatment Strategy for Elderly Patients with Soft Tissue Sarcoma
    Nakamura, Tomoki
    Sudo, Akihiro
    CURRENT ONCOLOGY REPORTS, 2022, 24 (05) : 563 - 571
  • [35] Incidence of bone and soft tissue sarcoma after radiotherapy: A cohort study of 295,712 Finnish cancer patients
    Virtanen, A
    Pukkala, E
    Auvinen, A
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (04) : 1017 - 1021
  • [36] Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma
    Martin-Liberal, Juan
    Perez, Ezequiel
    Garcia Del Muro, Xavier
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 39 - 50
  • [37] Retroperitoneal soft tissue Sarcomas: retrospective cohort study
    Ozsoy, Mehmet Sait
    Ekinci, Ozgur
    Acar, Mehmet
    Leblebici, Metin
    Isik, Arda
    Yildirim, Ayse Nur Toksoz
    Gunduz, Nesrin
    Alimoglu, Orhan
    BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2022, 21 (04): : 829 - 835
  • [38] Analysis of clinical outcomes of upper and lower extremity reconstructions in patients with soft-tissue sarcoma
    Kapoor, Trishul
    Banuelos, Joseph
    Adabi, Kian
    Moran, Steven L.
    Manrique, Oscar J.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (04) : 614 - 620
  • [39] Importance of intraoperative radiation therapy in the treatment of soft tissue sarcoma: Data at hand
    Sztankay A.
    memo - Magazine of European Medical Oncology, 2014, 7 (3) : 172 - 176
  • [40] Immediate Versus Staged Soft Tissue Reconstruction After Soft Tissue Sarcoma Resection Has Similar Wound and Oncologic Outcomes
    Lawrenz, Joshua M.
    Mesko, Nathan W.
    Marshall, Danielle C.
    Featherall, Joseph
    George, Jaiben
    Gordon, Jaymeson
    Vijayasekaran, Aparna
    Nystrom, Lukas M.
    Schwarz, Graham S.
    ANNALS OF PLASTIC SURGERY, 2020, 85 (02) : 163 - 170